Clinical implications of clozapine discontinuation: report of an NIMH workshop.
In September 1994, the National Institute of Mental Health convened a group of scientists to discuss the clinical effects of rapid clozapine discontinuation, especially in light of the introduction of risperidone for the treatment of schizophrenia. Despite concern over recent reports of clinical deterioration (psychotic exacerbations, somatic withdrawal symptoms, and extrapyramidal side effects) in a few patients abruptly discontinued from clozapine, there is currently insufficient information to determine the magnitude of the problems associated with clozapine withdrawal. However, clinicians are reminded that the withdrawal schedule for clozapine indicates a gradual tapering schedule (unless the patient is experiencing severe side effects); that switching patients from clozapine to risperidone does not mean that such tapering is unnecessary; and that the use of risperidone may not produce all of the same effects as clozapine in some treatment-refractory patients.
Shore
D
D
Division of Clinical and Treatment Research, NIMH, Rockville, MD 20857, USA.
Matthews
S
S
Cott
J
J
Lieberman
J A
JA
D014150:Antipsychotic Agents / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D018967:Risperidone; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis* / Q000523:psychology; D014481:United States; D014486:United States Food and Drug Administration
D014150:Antipsychotic Agents; D007555:Isoxazoles; D010880:Piperidines; D003024:Clozapine; D018967:Risperidone